Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Wall St slides as chip stocks fall, jobs data fuels hawkish Fed fears
- U.S. economy adds 172,000 jobs in May, topping expectations
- Citi warns global stock markets are the frothiest since 2008
- JPMorgan upgrades Tesla, sets new price target on robotaxi and Optimus potential
- Fed risks fueling a stock bubble by overlooking AI-driven inflation: BCA
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- LCI Industries names interim CEO as Jason Lippert retires
- Wall St slides as chip stocks fall, jobs data fuels hawkish Fed fears
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
July 29, 2019 6:45 AM EDTHERTFORDSHIRE, England and PITTSBURGH and NEW YORK, July 29, 2019 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan... More
